Leading pharmaceutical manufacturer, Aesica, has appointed Andrew Henderson as Business Development Manager at its head office in Newcastle.
Andrew will be based out of the company’s Head Office at Quorum Business Park and will support the existing business development team to promote the company’s Active Pharmaceutical Ingredient (API) development capabilities. He will specifically be responsible for business development around the API facilities at Aesica’s Cramlington site, including promotion of the kilo plant, pilot plant and all associated analytical facilities and expertise.
Originally from Ponteland in Newcastle, Andrew studied at Leeds University before returning to Newcastle to gain a PhD in Organic Medicinal Chemistry. Prior to joining Aesica, Andrew was a chemist and subsequently a member of the commercial team at Onyx Scientific, which he joined in 2006.
Speaking of his appointment Andrew says: “Aesica has a proven track record in providing primary and secondary contract manufacturing services to the highest possible standards and to have joined the team is a real privilege. The opportunity to be involved in larger scale pharmaceutical manufacturing was particularly appealing and I am keen to develop partnerships with emerging biotech and mid pharma organisations.
“It’s Aesica’s vision to become the leading supplier of Active Pharmaceutical Ingredients and Formulated Products and I hope that my expertise will play a crucial role in helping the company to achieve this objective.”
Adam Sims, Commercial Director, Aesica, adds: “Andrew’s appointment is strategically important to the business as we continue to enhance our global presence and reputation while expanding into new markets with a focus on developing our US market share. Our recent acquisition of R5 Pharmaceuticals demonstrates our commitment to enhancing our full service offering and will enable the business development team to further consolidate our portfolio of pharmaceutical and biotechnology clients.”
Aesica supplies contract development and contract manufacturing services for Active Pharmaceutical Ingredients and Formulated Products to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.
Its unique offer lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. It is this all-encompassing offer and its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.